Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cyclo Therapeutics, Inc. - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES
Ticker
Exchange
SIC #
Website
Latest Ticker
CYTH
Nasdaq
5122
cyclotherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cyclo Therapeutics, Inc.
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
- Mar 26th, 2025 10:50 am
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
- Mar 13th, 2025 9:50 pm
Is Cyclo Therapeutics, Inc. (CYTH) the Best Micro Cap Stock to Buy Now?
- Mar 7th, 2025 9:56 am
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
- Feb 7th, 2025 1:05 pm
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
- Jan 14th, 2025 1:05 pm
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
- Dec 11th, 2024 12:00 pm
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 14th, 2024 1:05 pm
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
- Nov 7th, 2024 12:14 am
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
- Oct 21st, 2024 12:00 pm
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
- Sep 5th, 2024 1:05 pm
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
- Aug 22nd, 2024 10:50 am
Cyclo Therapeutics Second Quarter 2024 Earnings: Misses Expectations
- Aug 17th, 2024 12:55 pm
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aug 15th, 2024 1:00 pm
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
- Jul 29th, 2024 1:05 pm
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
- Jun 25th, 2024 1:25 pm
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
- Jun 14th, 2024 8:01 pm
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
- May 30th, 2024 1:00 pm
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- May 16th, 2024 12:05 pm
Scroll